PPARα L162V polymorphism alters the potential of n-3 fatty acids to increase lipoprotein lipase activity

Molecular Nutrition and Food Research

Volumn 54, Issue 4, 2010, Pages 543-550

  Rudkowska, Iwona ^a   Caron Dorval, Dominique ^a   Verreault, Mélanie ^a   Couture, Patrick ^a   Deshaies, Yves ^b   Barbier, Olivier ^a   Vohl, Marie Claude ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Docosahexaenoic acid; Eicosapentanoic acid; Lipoprotein lipase; PPAR Polymorphism; Triglycerides

Indexed keywords

DOCOSAHEXAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; LIPID; LIPOPROTEIN LIPASE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CHEMISTRY; DIET; ERYTHROCYTE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; GENETICS; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; TUMOR CELL LINE;

ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DIET; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ERYTHROCYTES; FATTY ACIDS; FATTY ACIDS, OMEGA-3; GENE EXPRESSION; GENOTYPE; HUMANS; LIPIDS; LIPOPROTEIN LIPASE; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PPAR ALPHA; TRANSFECTION;

EID: 77951046543     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200900085     Document Type: Article

References (43)

1. Balk, E. M., Lichtenstein, A. H., Chung, M., Kupelnick, B. et al., Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 189, 19-30.
2. Harris, W. S., n-3 fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr. 1997, 65, 1645S-1654S.
3. Harris, W. S., Bulchandani, D., Why do omega-3 fatty acids lower serum triglycerides? Curr. Opin. Lipidol. 2006, 17, 387-393.
4. Duval, C., Muller, M., Kersten, S., PPARalpha and dyslipidemia. Biochim. Biophys. Acta 2007, 1771, 961-971.
5. Khan, S., Minihane, A. M., Talmud, P. J., Wright, J. W. et al., Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J. Lipid Res. 2002, 43, 979-985.
6. Staels, B., Schoonjans, K., Fruchart, J. C., Auwerx, J., The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Biochimie 1997, 79, 95-99.
7. Simo, I. E., Yakichuk, J. A., Ooi, T. C., Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemiaand hypertriglyceridemia syndrome. Atherosclerosis 1993, 100, 55-64.
8. Simpson, H. S., Williamson, C. M., Olivecrona, T., Pringle, S. et al., Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 1990, 85, 193-202.
9. Desager, J. P., Horsmans, Y., Vandenplas, C., Harvengt, C., Pharmacodynamic activity of lipoprotein lipase and hepatic lipase,and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate(100or200mg/day) or micronised fenofibrate (200mg/day) therapy for 23 days. Atherosclerosis 1996, 124(Suppl), S65-S73.
10. Tai, E. S., Demissie, S., Cupples, L. A., Corella, D. et al., Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 805-810.
11. Tanaka, T., Ordovas, J. M., Delgado-Lista, J., Perez-Jimenez, F. et al., Peroxisome proliferator-activated receptor alpha polymorphisms and postprandial lipemia in healthy men. J. Lipid Res. 2007, 48, 1402-1408.
12. Uthurralt, J., Gordish-Dressman, H., Bradbury, M., Tesi- Rocha, C. et al., PPARalpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med. Genet. 2007, 8, 55.
13. Flavell, D. M., Pineda Torra, I., Jamshidi, Y., Evans, D. et al., Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 2000, 43, 673-680.
14. Robitaille, J., Brouillette, C., Houde, A., Lemieux, S. et al., Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J. Hum. Genet. 2004, 49, 482-489.
15. Vohl, M. C., Lepage, P., Gaudet, D., Brewer, C. G. et al., Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J. Lipid Res. 2000, 41, 945-952.
16. Sapone, A., Peters, J. M., Sakai, S., Tomita, S. et al., The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 2000, 10, 321-333.
17. Tai, E. S., Corella, D., Demissie, S., Cupples, L. A. et al., Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J. Nutr. 2005, 135, 397-403.
18. Paradis, A. M., Fontaine-Bisson, B., Bosse, Y., Robitaille, J. et al., The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. Am. J. Clin. Nutr. 2005, 81, 523-530.
19. Sampath, H., Ntambi, J. M., Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu. Rev. Nutr. 2005,25,317-340.
20. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 2001, 285, 2486-2497.
21. McNamara, J. R., Schaefer, E. J., Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin. Chim. Acta 1987, 166, 1-8.
22. Burstein, M., Samaille, J., On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins. Clin. Chim. Acta 1960, 5, 609.
23. Albers, J. J., Warnick, G. R., Wiebe, D., King, P. et al., Multi- laboratory comparison of three heparin-Mn21precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin. Chem. 1978, 24, 853-856.
24. Friedewald, W. T., Levy, R. I., Fredrickson, D. S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18, 499-502.
25. Watson, T. D., Tan, C. E., McConnell, M., Clegg, S. K. et al., Measurement and physiological significance of lipoprotein and hepatic lipase activities in preheparin plasma. Clin. Chem. 1995, 41, 405-412.
26. Vu-Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J. et al., Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol. Cell. Biol. 1996, 16, 3350-3360.
27. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A. M., Heyman, R. A. et al., PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996, 15, 5336-5348.
28. Akbiyik, F., Ray, D. M., Bozkaya, H., Demirpence, E., Ligand- and species-dependent activation of PPARalpha. Cell Physiol. Biochem. 2004, 14, 269-276.
29. Jungling, E., Kammermeier, H., A one-vial method for routine extraction and quantification of free fatty acids in blood and tissue by HPLC. Anal. Biochem. 1988, 171, 150-157.
30. Caron-Dorval, D., Paquet, P., Paradis, A. M., Rudkowska, I. et al., Effect of the PPAR-Alpha L162V Polymorphism on the Cardiovascular Disease Risk Factor in Response to n-3 Polyunsaturated Fatty Acids. J. Nutrigenet. Nutrigenomics 2008,1,205-212.
31. Armstrong, M. B., Towle, H. C., Polyunsaturated fatty acids stimulate hepatic UCP-2 expression via a PPARalphamediated pathway. Am. J. Physiol. Endocrinol. Metab. 2001,281, E1197-E1204.
32. Harris, W. S., Connor, W. E., Alam, N., Illingworth, D. R., Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J. Lipid Res. 1988, 29, 1451-1460.
33. Weintraub, M. S., Zechner, R., Brown, A., Eisenberg, S. et al., Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J. Clin. Invest. 1988, 82, 1884-1893.
34. Desager, J. P., Dricot, J., Harvengt, C., Hypotriglyceridemic action of omega-3 fatty acids in healthy subjects does not occur by enhanced lipoprotein lipase and hepatic lipase activities. Res. Commun. Chem. Pathol. Pharmacol. 1989, 65,269-272.
35. Bagdade, J. D., Buchanan, W. E., Levy, R. A., Subbaiah, P. V. et al., Effects of omega-3 fish oils on plasma lipids, lipoprotein composition, and postheparin lipoprotein lipase in women with IDDM. Diabetes 1990, 39, 426-431.
36. Nozaki, S., Garg, A., Vega, G. L., Grundy, S. M., Postheparin lipolytic activity and plasma lipoprotein response to omega-3 polyunsaturated fatty acids in patients with primary hypertriglyceridemia. Am. J. Clin. Nutr. 1991, 53, 638-642.
37. Kasim-Karakas, S. E., Herrmann, R., Almario, R., Effects of omega-3 fatty acids on intravascular lipolysis of very-low- density lipoproteins in humans. Metabolism 1995, 44, 1223-1230.
38. Harris, W. S., Lu, G., Rambjør, G. S., Walen, A. I. et al., Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am. J. Clin. Nutr. 1997, 66,254-260.
39. Demonty, I., Deshaies, Y., Lamarche, B., Jacques, H., Cod protein lowers the hepatic triglyceride secretion rate in rats. J. Nutr. 2003, 133, 1398-1402.
40. Scanu, A. M., Edelstein, C., Fless, G. M., Eisenbart, J. et al., Postprandial lipoprotein(a) response to a single meal containing either saturated or omega-3 polyunsaturated fatty acids in subjects with hypoalphalipoproteinemia. Metabolism 1992, 41, 1361-1366.
41. Auwerx, J., Schoonjans, K., Fruchart, J. C., Staels, B., Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C- III genes by activating the nuclear receptor PPAR. Atherosclerosis 1996, 124(Suppl), S29-S37.
42. Park, Y., Harris, W. S., Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J. Lipid Res. 2003,44,455-463.
43. Grimsgaard, S., Bonaa, K. H., Hansen, J. B., Nordøy, A., Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am. J. Clin. Nutr. 1997,66,649-659.